NCT07703631 Characterization, Health Resource Utilization and Biomarkers in Early-stage
| NCT ID | NCT07703631 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Universitario San Ignacio |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 267 participants |
| Start Date | 2026-01-16 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 267 participants in total. It began in 2026-01-16 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lung cancer is the leading cause of cancer incidence and mortality worldwide as it is for highand middle-income countries. A major decline in lung cancer incidence and mortality might be mainly due to the reduction on tobacco smoking prevalence since survival rates has not significantly improved despite the advances in diagnosis and treatment. Lung cancer is broadly classified into two categories, based on the type of tumor cells: small cell lung cancer and non-small cell lung cancer. Among them, is the most frequent type and is subdivided into histological types: Adenocarcinoma Squamous cell carcinoma of the lung arge cells carcinoma. Additional biological complexity has been uncovered through intense research in recent years, including different molecular subtypes with specific targetable characteristics. Diagnosing cancer at early stages (I or II) is critical as it may offer patients a better prognosis in terms of overall survival )for instance, patients diagnosed at stage IA have a 5- year survival rate higher than 80%, compared to less than 10% for those diagnosed at stage IV ostly because the possibility for most patients to undergo surgery or radiotherapy, as potentially curative interventions. A study among resectable lung cancer in Colombia found overall 3-year survival for patients with and without relapse 78% and 96%, respectively Early-stage may have a considerable recurrence rate despite of opportune and complete resections and the Colombian study found stage II (T3 and N1 as independent factors) and pleura invasion associated with a higher risk of recurrence.
Eligibility Criteria
Inclusion Criteria: All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee to ensure that the subject qualifies for the study. 1. Patients ≥ 18 years old 2. Patients diagnosed with NSCLC (stage IA, IB, II, IIIA, and IIIB) 3. Clinical records available Exclusion Criteria: 1. Patients with another primary tumor diagnosed (synchronic tumor) 2. Patients from insurances regimens other than the public and private system. 3. Patients with advanced/metastatic disease 4. Patients diagnosed with resectable stage IA, IB, II, IIIA, and IIIB NSCLC in Colombia that went under immunotherapy treatment
Contact & Investigator
Raúl Murillo, Dr
PRINCIPAL INVESTIGATOR
Hospital Universitario San Ignacio
Frequently Asked Questions
Who can join the NCT07703631 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07703631 currently recruiting?
Yes, NCT07703631 is actively recruiting participants. Contact the research team at rmurillo@husi.org.co for enrollment information.
Where is the NCT07703631 trial being conducted?
This trial is being conducted at Bogotá, Colombia.
Who is sponsoring the NCT07703631 clinical trial?
NCT07703631 is sponsored by Hospital Universitario San Ignacio. The principal investigator is Raúl Murillo, Dr at Hospital Universitario San Ignacio. The trial plans to enroll 267 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.